Chargement en cours...
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
Enregistré dans:
| Publié dans: | Clin Case Rep |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7069848/ https://ncbi.nlm.nih.gov/pubmed/32185037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2688 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|